Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Kimberly Maersk-Moller, the Chief Commercial Officer of MiMedx Group, Inc. (NASDAQ:MDXG), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Maersk-Moller sold 1,759 shares of common stock on March 17, 2025, at a price of $8.04 per share. The total transaction amounted to $14,142. The stock, currently trading at $8.09, has shown strong momentum with a 32% gain over the past six months. With a market capitalization of $1.19 billion, MiMedx maintains a "GREAT" financial health score according to InvestingPro analysis.
Following this sale, Maersk-Moller holds 309,077 shares directly. The sale was conducted in connection with the vesting of a previously granted restricted stock unit award, with the proceeds used to cover tax withholding liabilities related to the vesting. Analysts maintain a Strong Buy consensus on the stock, with price targets ranging from $12 to $16. InvestingPro analysis suggests the stock is currently overvalued, with subscribers having access to detailed valuation metrics and 8 additional ProTips for MDXG.
In other recent news, MiMedx Group Inc . reported its fourth-quarter 2024 financial results, highlighting earnings per share (EPS) of $0.07, which exceeded the analysts’ forecast of $0.06. The company also reported revenue of $93 million, surpassing the expected $89.4 million and marking a 7% year-over-year increase. MiMedx ended the year with $104 million in cash, reflecting a $16 million increase during the fourth quarter. The company anticipates high single-digit sales growth in 2025, with expectations of maintaining an adjusted EBITDA margin above 20%.
The firm also projects low double-digit growth following the implementation of changes to Medicare Local Coverage Determination (LCD). Despite these positive financials, MiMedx’s stock experienced a slight decline in after-hours trading. In terms of strategic developments, MiMedx is continuing the market release of Heliogen, its first xenograft product, which is expected to contribute significantly in 2025. Additionally, the company is actively addressing ongoing legal disputes with competitors and is preparing for potential market changes due to Medicare reimbursement adjustments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.